The glycosylated haemoglobin A1c and albuminuria of patients with type 2 Diabetes in The Republic of Srpska: a cross sectional study
Abstract
Background: Glycosylated haemoglobin (HbA1c) is currently the gold standard for glucose monitoring in patients with diabetes. The aim of the present study was to examine the level of success in implementing international guideline targets with regard to glycaemic control in patients with type 2 Diabetes in The Republic of Srpska. This study also aimed to determine the association of albuminuria with glycaemic control and lipid levels in this patient population.
Methods: Participating diabetic patients were those registered in the project titled ’’Estimation of the quality of glycoregulation and presence of vascular complications in persons with Diabetes in The Republic of Srpska.” The study was conducted as a cross-sectional study, including 1037 patients. The HbA1c was determined by a turbidimetric inhibition immunoassay used Roche Diagnostics. Total cholesterol, triglycerides, LDL-C, and HDL-C were determined by reagents from Roche Diagnostics (Roche Diagnostics, Mannheim, Germany) as well as albumin and creatinine in the urine.
Results: Mean value for HbA1c was 7.35±1.61% (57± 18 mmol/mol). The 49.46% of all participants achieved target values of HbA1c ( <7% or 53 mmol/mol) and 40.30% had albumin to creatinine ratio (ACR) <30 mg/g. When the patients were divided according to HbA1c (with HbA1c <7% and HbA1c ≥7.0% ) the ACR values were different among these groups (39.00 vs. 79.50, p<0.001). Also, we found no significant difference with respect to lipid status between the groups.
Conclusion: Patients with type 2 Diabetes in The Republic of Srpska, in a large percentage, did not meet targets for glycaemic control. Improvements are necessary in treatment and maintenance of this disease process to ensure achievement of goals in management of diabetes, which in turn would decrease longstanding complications of type 2 Diabetes.
Key words: type 2 Diabetes, HbA1c, albuminuria, lipids.
References
REFERENCES
International Diabetes Federation. IDF Diabetes atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.
Standards of Medical Care in Diabetes-2016: Summary of Re-visions. Diabetes Care 2016; 39 Suppl 1: S4‒5.
World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009.
American Diabetes Association. 10. Microvascular Complications and Foot Care. Diabetes Care 2017; 40(Suppl 1): S88‒S98.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. UKPDS GROUP.Development and progression of neph-ropathy in type 2 diabetes: the United KingdomProspective Diabetes Study (UKPDS 64). Kidney Int 2003; 63(1): 225‒32.
Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Mul-tiple Risk Factor Intervention Trial. JAMA 1997; 278(23): 2069–74.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241(19): 2035–8.
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in con-gestive heart failure: the Framingham study. Am J Cardiol 1974; 34 (1): 29–34.
Brand FN, Abbott RD, Kanel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 1989; 38 (4): 504–9.
Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus:a sys-tematic overview of the literature. Arch Intern Med 1997; 157(13): 1413–8.
Valmadrid CT, Klein R, Moss SE, Klein BE.The risk of cardi-ovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mel-litus. Arch Intern Med 2000; 60 (8): 1093–100.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560‒72.
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010; 376 (9739): 419‒30.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129‒39.
American Diabetes Association. Glycemic targets. Sec. 5. In Stan-dards of Medical Care in Diabetesd 2016. Diabetes Care 2016; 39(Suppl 1): S39–S46.
Roche Tina-quant Hemoglobin A1c II package insert. Vol. 12. Indianapolis, IN: Roche Diagnostics; 2007.
Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985-1986; 9(2): 85‒95.
Liebl A, Mata M, Eschwège E; ODE-2 Advisory Board. Eval-uation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45(7): S23‒8.
Stone MA, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C, et al. GUIDANCE Study Group. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUID-ANCE) study. Diabetes Care 2013; 36(9): 2628‒38.
Gorter KJ, Wens J, Khunti K,Klaramunt XC, Topsever P, Drivsholm T, et al. The European EUCCLID pilot study on care and complications in an unselected sample of people with type 2 diabetes in primary care. Prim Care Diabetes 2010; 4(1): 17–23.
Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet 2005; 365(9459): 556‒7.
Shankar A, Klein R, Moss SE, Klein BE, Wong TY.The relation-ship between albuminuria and hypercholesterolemia. J Neph-rol 2004; 17(5): 658–65.
Baragetti A,Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, et al. High- density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 2013; 274(3): 252–62.
Kim YI, Kim CH, Choi CS, Chung YE, Lee MS, Lee SI, et al. Microalbuminuria is associated with the insulin resistance syn-drome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract 2001;52 (2):145–52.
Sun K, Lin D, Li F, Huang C, Qi Y, Xue S, et al. Discordant as-sociations of lipid parameters with albuminuria and chronic kidney disease: a population-based study. Lipids Health Dis 2015; 14: 152.
de Boer IH, Astor BC, Kramer H, Palmas W, Rudser K, Seliger SL, et al. Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2008; 197(1): 407–14.
Nam GE, Han K, Kim DH, Park YG, Yoon YJ, Kim YE, et al. Relationship between dyslipidemia and albuminuria in predia-betic adults: the Korea National Health and Nutrition Exami-nation Survey 2011-2012. Endocrine 2015; 48(2): 557‒65.
Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, et al. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 di-abetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One 1015; 10(5): e0125512.
Tien KJ, Tu ST, Chen HC, Hsiao JY, Hsieh MC. Triglycerides are independently associated with albuminuria in Taiwanese Type 2 diabetic patients. J Endocrinol Invest 2012; 35(9): 800‒3.
Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis 2014; 233(1): 260‒7.